Are SNOA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SNOA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / SNOA / insiders

TNON (30) INBS (27) NVNO (33) WOK (51) ⌘ Pro Terminal →

Sonoma Pharmaceuticals Inc. (SNOA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.10 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.10

Sonoma Pharmaceuticals Inc. (SNOA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNOA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.10 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, SNOA ranks #657 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNOA compare to TNON and INBS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNOA?

▼

Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.10 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNOA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY SNOA SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.18-2.5% Next Q

Q2 (-2Q)

Grade E$1.15+0% Next Q

Q3 (-1Q)

Grade E$1.15-4.3% Next Q

Current

Grade E$1.10-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNOA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNOA currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.16) forces dealer call-delta covering toward $4.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNOA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SNOA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SNOA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SNOA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNOA)

✓Walkthrough of SNOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.84%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.20H $1.20L $1.10C $1.10VOL 85.8K

RES: $1.51SUP: $1.07SMA50: $1.23SMA200: $1.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNOA Butterfly Map → + Track SNOA →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +36.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SNOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNOA)

Health Care Rank #657 of 1015 ⚔️ TNON vs SNOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNOA vs. TNON, INBS, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sonoma Pharmaceuticals Inc. (SNOA) ranks #657 by composite RQD confidence (34/100, grade E) and #936 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, SNOA leads on earnings valuation at N/A trailing P/E, while SNOA leads on capital efficiency and profitability with -35.0% ROIC and 38.0% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with SNOA at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNOA ACTIVE Sonoma Pharmaceuticals Inc.	E	34/100	—	38.0%	-35.0%	0.00%	$5.3M	Benchmark Subject
TNON Tenon Medical Inc.	E	30/100	—	59.8%	-35.0%	-5.85%	$5.5M	/tnon-vs-snoa →
INBS Intelligent Bio Solutions Inc.	E	27/100	—	40.8%	-35.0%	-5.68%	$5.8M	/inbs-vs-snoa →
NVNO enVVeno Medical Corporation	E	33/100	—	—	-35.0%	+2.08%	$4.7M	/nvno-vs-snoa →
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	0.00%	$4.5M	/wok-vs-snoa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001367083 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported GAAP revenue of $19.5M (+36.7% vs. FY2024 revenue of $14.3M , and +53.3% cumulative change since FY2023) , GAAP net income of $3.2K, operating cash flow of -$3.9M, and free cash flow of -$4.1M (-2355.4% YoY). On the balance sheet, SNOA closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$19.5M	$3.2K	-$3.9M	-$4.1M	$13.6M	—
FY2024 (FY)	2025-03-31	$14.3M	$3.5K	-$88.0K	-$168.0K	$13.7M	—
FY2023 (FY)	2024-03-31	$12.7M	$4.8K	-$2.4M	-$2.4M	—	—

3. SNOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SNOA compare to TNON and INBS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SNOA?

Where is SNOA trading relative to its 50-day, 200-day, and 52-week technical levels?

SNOA last traded at $1.10 (0.00% on volume of 42,243 shares), positioning the stock -10.57% below its 50-day simple moving average ($1.23) and -34.52% below its 200-day simple moving average ($1.68). Across its 52-week range of $0.85 to $3.97, SNOA sits at the 8.0% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.24).

Direct Sub-Reports: SNOA RQD Cockpit SNOA 12M Forecast SNOA Earnings & Move SNOA Dividends & DRIP SNOA Insiders & 13F SNOA Whale Options SNOA Profit Sankey SNOA News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

SNOA — Sonoma Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sonoma Pharmaceuticals Inc. (SNOA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.10 (0.00% 1D, market capitalization $5.3M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 38.0%, operating margin of -12.6%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sonoma Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The market capitalization is $0.0B. — The specific products, customer base, and revenue model are not described in the provided sources.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported $19.5M in annual revenue (up from $14.3M in FY2024, +36.7% YoY) and $3.2K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.7M revenue, $4.8K net income) through FY2025, SNOA scaled operating cash flow to -$3.9M and free cash flow to -$4.1M, backed by $13.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.85 – $3.97 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), SNOA carries a macro regime beta of 1.00 and gross margin of 38.0%.

Key Question #1: Can SNOA sustain or expand its -12.6% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$4.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SNOA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SNOA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sonoma Pharmaceuticals Inc. (SNOA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNOA Debate Forum (3) ↓

🟡 MARKET WIRE TradingKey • 22h ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Sonoma Pharmaceuticals Q2 2026 Earnings: Narrow EPS Miss Keeps Shares Under Pressure - Dividend Growth Analysis

https://www.dars.gov.et/ report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Unusual Volume Stocks & Volume Spikes Today

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago

Kane Biotech signs Canadian distribution agreement for revyve wound care

Mugglehead Investment Magazine report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNOA Bull vs. Bear Conversation Board — What's Your Call at $1.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNOA 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.40 (+27.3%)

📌 Pinned Debate

Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the ra

Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the rating.. When you look under the hood at SNOA, Fundamental Cash Engine is 5/20 with 38.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $3.97. My 12M target is $1.40.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SNOA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.95 (-13.6%)

Spot @ $1.10

ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.

ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.. Look at the math on SNOA: paying current EV/EBITDA multiples for -35.0% ROIC and -12.6% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $0.97 before getting long.